Pfizer (NYSE:PFE) Shares Down 1.6% - Here's What Happened

Key Points

• Pfizer shares fell 1.6% to about $26.61 in midday trading, with volume down 15% from the average daily level.
• Recent quarterly results beat expectations, with $0.77 in EPS and $15.03 billion in revenue; Pfizer also reported 5% growth in non-COVID products, raised its 2026 outlook, and reiterated its approximately $9.7 billion cost-savings target.
• Despite the recovery prospects and 6.5% dividend yield, investors remain concerned about declining COVID-product sales, upcoming patent losses, sharply lower earnings, and the sustainability of the dividend. Analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price fell 1.6% during mid-day trading on Tuesday . The stock traded as low as $26.47 and last traded at $26.6110. 36,266,027 shares were traded during mid-day trading, a decline of 15% from the average daily volume of 42,457,094 shares. The stock had previously closed at $27.05.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s second-quarter update was encouraging: non-COVID products grew 5%, the company raised its 2026 guidance, and management reiterated a target of approximately $9.7 billion in cost savings. The results suggest Pfizer’s broader portfolio is beginning to offset pandemic-related revenue declines. Pfizer Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analysts highlighted Pfizer’s second-quarter earnings beat and raised 2026 revenue outlook as evidence that the company may be turning a corner, although the post-COVID transition remains challenging. Pfizer Rises Almost 7% Post Q2 Results
• Positive Sentiment: The stock’s sizable dividend yield remains a key attraction for income investors, particularly compared with the S&P 500’s average yield. Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?
• Neutral Sentiment: Pfizer extended its advance for a seventh consecutive session, indicating improved investor sentiment following its quarterly results, though the extended rally may also leave the shares vulnerable to profit-taking. Pfizer Extends Rally to Seventh Straight Session
• Neutral Sentiment: Pfizer and BioNTech received European authorization for an updated COVID-19 vaccine, but the companies are pursuing different post-pandemic strategies; Pfizer is emphasizing scale and cost reductions while broadening its non-COVID pipeline. Pfizer vs BioNTech: Which Pharma Giant Is Better Positioned for the Post-COVID Era?
• Negative Sentiment: Investors remain concerned that Pfizer’s earnings have fallen sharply this year and that its roughly 6.4% dividend yield could become difficult to maintain, raising the risk of a future dividend reduction. Pfizer's Earnings Have Declined 58% This Year
• Negative Sentiment: Declining COVID product sales and upcoming patent losses continue to cloud Pfizer’s long-term growth outlook, potentially limiting the benefit of cost cuts and pipeline expansion. Is Pfizer Turning a Corner as Its Non-COVID Pipeline Widens?

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and lowered their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Pfizer in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.28.

Pfizer Stock Performance

The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market cap of $151.67 billion, a P/E ratio of 35.01 and a beta of 0.34. The business's 50 day simple moving average is $25.05 and its 200 day simple moving average is $26.18.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the company posted $0.78 earnings per share. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's payout ratio is 226.32%.

Institutional Trading of Pfizer

Several hedge funds have recently bought and sold shares of PFE. Handelsbanken Fonder AB raised its holdings in shares of Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock worth $59,295,000 after buying an additional 232,528 shares during the period. Vanguard Group Inc. grew its position in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. KBC Group NV increased its stake in Pfizer by 8.3% in the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company's stock worth $228,924,000 after purchasing an additional 706,426 shares during the period. North Dakota State Investment Board purchased a new stake in Pfizer in the fourth quarter worth $5,348,000. Finally, PFA Pension Forsikringsaktieselskab bought a new stake in shares of Pfizer during the fourth quarter worth $76,833,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source